S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:DTIL

Precision BioSciences (DTIL) Stock Price, News & Analysis

$13.56
+0.58 (+4.47%)
(As of 03/28/2024 ET)
Today's Range
$13.04
$13.80
50-Day Range
$10.80
$18.56
52-Week Range
$8.25
$28.44
Volume
191,191 shs
Average Volume
130,925 shs
Market Capitalization
$55.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.00

Precision BioSciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
342.5% Upside
$60.00 Price Target
Short Interest
Healthy
4.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
-0.12mentions of Precision BioSciences in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$64,854 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.71) to ($6.31) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.22 out of 5 stars

Medical Sector

174th out of 938 stocks

Biological Products, Except Diagnostic Industry

22nd out of 148 stocks

DTIL stock logo

About Precision BioSciences Stock (NASDAQ:DTIL)

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

DTIL Stock Price History

DTIL Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Precision BioSciences Inc Q4 Loss decreases, but misses estimates
Earnings Preview: Precision BioSciences
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Precision BioSciences, Inc. (PBS0.F)
Precision BioSciences Sinks 30%; Sets $40 Mln Stock Offering
See More Headlines
Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:DTIL
Fax
N/A
Employees
115
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$60.00
High Stock Price Target
$60.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+342.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-111,640,000.00
Net Margins
-140.60%
Pretax Margin
-164.10%

Debt

Sales & Book Value

Annual Sales
$25.10 million
Book Value
$16.36 per share

Miscellaneous

Free Float
3,853,000
Market Cap
$55.05 million
Optionable
Optionable
Beta
1.56
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Michael Amoroso (Age 45)
    President, CEO & Director
    Comp: $979.04k
  • Mr. John Alexander Kelly R.Ph. (Age 57)
    CFO & Principal Accounting Officer
    Comp: $623.58k
  • Mr. Dario Scimeca (Age 48)
    General Counsel & Secretary
    Comp: $576.43k
  • Dr. Jefferson J. Smith Ph.D. (Age 51)
    Co-Founder & Chief Research Officer
  • Mei Burris
    Director of Investor Relations & Finance
  • Mr. Bruce Stevens
    Vice President of Quality & Compliance
  • Maurissa Messier
    Senior Director of Corporate Communications
  • Ms. Juli Blanche
    Chief People Officer
  • Mr. Garrett Gincley
    Head of Manufacturing
  • Dr. Alan F. List M.D. (Age 69)
    Chief Medical Officer

DTIL Stock Analysis - Frequently Asked Questions

Should I buy or sell Precision BioSciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DTIL shares.
View DTIL analyst ratings
or view top-rated stocks.

What is Precision BioSciences' stock price target for 2024?

2 brokers have issued 12 month target prices for Precision BioSciences' shares. Their DTIL share price targets range from $60.00 to $60.00. On average, they anticipate the company's stock price to reach $60.00 in the next year. This suggests a possible upside of 342.5% from the stock's current price.
View analysts price targets for DTIL
or view top-rated stocks among Wall Street analysts.

How have DTIL shares performed in 2024?

Precision BioSciences' stock was trading at $10.95 at the beginning of the year. Since then, DTIL shares have increased by 23.8% and is now trading at $13.56.
View the best growth stocks for 2024 here
.

When is Precision BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our DTIL earnings forecast
.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($5.70) EPS for the quarter, beating the consensus estimate of ($17.70) by $12.00. The firm had revenue of $24.04 million for the quarter, compared to analysts' expectations of $8.54 million. Precision BioSciences had a negative net margin of 140.60% and a negative trailing twelve-month return on equity of 189.47%. During the same quarter in the prior year, the company posted ($15.00) earnings per share.

What ETF holds Precision BioSciences' stock?

Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio.

When did Precision BioSciences' stock split?

Precision BioSciences's stock reverse split on the morning of Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

When did Precision BioSciences IPO?

Precision BioSciences (DTIL) raised $126 million in an initial public offering on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Capital World Investors (4.20%), Vanguard Group Inc. (3.90%), Vanguard Group Inc. (117.11%), Blue Owl Capital Holdings LP (0.50%), Goldman Sachs Group Inc. (12.16%) and Corient Private Wealth LLC (0.19%). Insiders that own company stock include Alan List, Dario Scimeca, David S Thomson, David S Thomson, Derek Jantz, John Alexander Kelly, Matthew R Kane, Matthew R Kane, Michael Amoroso and Vince Craig Hopkin.
View institutional ownership trends
.

How do I buy shares of Precision BioSciences?

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DTIL) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners